Teeru Bihani

Elacestrant (RAD1901), a Selective Estrogen Receptor Degrader (SERD), Has Antitumor Activity in Multiple ER+ Breast Cancer Patient-derived Xenograft Models

Teeru Bihani, Hitisha Patel, Heike Arlt et al. · Clinical Cancer Research · 2017 · 160 citations

Medicine, Oncology, Pharmacology +14

AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules

Sylvie M. Guichard, Jon Curwen, Teeru Bihani et al. · Molecular Cancer Therapeutics · 2015 · 125 citations · Full text

Medicine, Oncology, Pharmacology +17

Enhanced selenium effect on growth arrest by BiP/GRP78 knockdown in p53-null human prostate cancer cells

Ke Zu, Teeru Bihani, A Lin et al. · Oncogene · 2005 · 107 citations · Full text

Medicine, Biochemistry, Oncology +12

The protein kinase Akt1 regulates the interferon response through phosphorylation of the transcriptional repressor EMSY

Scott A. Ezell, Christos Polytarchou, Maria Hatziapostolou et al. · Proceedings of the National Academy of Sciences · 2012 · 82 citations · Full text

Life Sciences, Cancer Biology, Molecular Biology +17

Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors

Hitisha Patel, Nianjun Tao, Kyung-Min Lee et al. · Breast Cancer Research · 2019 · 78 citations · Full text

Medicine, Oncology, Pharmacology +17